Sorry Scott, yes I'm here in the background practicing my patience waiting for more news from the company ha.
Yeah the MSA-ai poster has some steep correlation lines don't you think. Keen for 202 news soon.. will get my head back into the 202 study and what we might hope for with those 12 months results.. you have any particular hopes for the 202 results? IMO continuing trend of earlier stage pts performing better would be good, some of those initial responders still responding/stabilised at 12 months also be good. Additional responders showing disease slowing between 6-12 month mark very very good, but not getting ahead of myself with that. Really just hoping results feed into 201 narrative nicely in terms of drug activity, trend of efficacy and safety in this more advanced cohort. Cheers
ATH Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)